Summary & Overview
HCPCS Q5133: Tocilizumab-bavi (tofidence) injection, 1 mg
HCPCS Level II code Q5133 designates a 1 mg unit of tocilizumab-bavi (tofidence), a biosimilar formulation of the interleukin-6 receptor inhibitor tocilizumab. As a billable biologic drug unit, this code is relevant to administration of injectable biologic therapy in outpatient infusion centers, physician offices, and specialty clinics. Nationally, biosimilar HCPCS codes like Q5133 matter for cost management, formulary placement, and drug benefit design across public and commercial payers.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield plans, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical intent and service context, payer coverage considerations, common modifiers used in billing, and guidance on typical sites of service. The publication also summarizes benchmarks and policy updates that influence reimbursement and utilization for biosimilar injectable therapies, and provides clinical context about the drug class and administration scenarios where the code applies.
This briefing is intended for revenue cycle leaders, clinical administrators, and policy analysts seeking clear, nationally focused information on billing, coverage, and operational implications of HCPCS Level II code Q5133.
Billing Code Overview
HCPCS Level II code Q5133 represents an injection of tocilizumab-bavi (tofidence), biosimilar, 1 mg. This code denotes a biologic intravenous or subcutaneous injectable product used in conditions where tocilizumab or its biosimilars are clinically indicated. Service type: biologic drug administration / injectable medication. Typical site of service: infusion center, outpatient clinic, or physician office.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with an inflammatory or autoimmune condition (for example, rheumatoid arthritis or giant cell arteritis) who requires parenteral interleukin-6 receptor blockade. The patient presents to an outpatient infusion center, specialty clinic, or physician office for administration of a tocilizumab biosimilar presented as Q5133 (tocilizumab-bavi, 1 mg). Prior to injection, the clinical workflow includes verification of indication and dosing, review of recent lab results (including liver function tests and absolute neutrophil count), screening for active infections and tuberculosis, review of prior biologic therapy response, and insurance eligibility/authorization checks. The clinician documents informed consent and baseline vital signs. The medication is prepared per pharmacy or clinic protocol, and the calculated dose is drawn and administered via subcutaneous injection or intravenous infusion route as appropriate for the specific product presentation. Post-administration observation occurs per protocol to monitor for infusion or injection reactions. Documentation includes the Q5133 HCPCS code, the exact units administered (mg), lot number, and applicable modifier(s) to reflect circumstances of service, billing, or wastage (e.g., JW). Typical sites of service are outpatient infusion centers, rheumatology or immunology clinics, and physician offices. Common payors include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|